| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing.
|
PLoS One
|
2013
|
1.10
|
|
2
|
Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
|
Int J Cancer
|
2012
|
0.97
|
|
3
|
KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
|
Ann Surg Oncol
|
2014
|
0.96
|
|
4
|
Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker.
|
Int J Cancer
|
2013
|
0.93
|
|
5
|
Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study.
|
Psychiatry Investig
|
2010
|
0.92
|
|
6
|
Rapid identification of potentially probiotic Bifidobacterium species by multiplex PCR using species-specific primers based on the region extending from 16S rRNA through 23S rRNA.
|
FEMS Microbiol Lett
|
2005
|
0.88
|
|
7
|
Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt.
|
Bioorg Med Chem Lett
|
2006
|
0.86
|
|
8
|
Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.
|
J Clin Endocrinol Metab
|
2014
|
0.83
|
|
9
|
Rapid identification of probiotic Lactobacillus species by multiplex PCR using species-specific primers based on the region extending from 16S rRNA through 23S rRNA.
|
FEMS Microbiol Lett
|
2004
|
0.83
|
|
10
|
Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.
|
Cancer Chemother Pharmacol
|
2010
|
0.81
|
|
11
|
Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer.
|
Jpn J Clin Oncol
|
2005
|
0.80
|
|
12
|
A survey on hair modeling: styling, simulation, and rendering.
|
IEEE Trans Vis Comput Graph
|
2007
|
0.78
|
|
13
|
Effects of peptides derived from BACE1 catalytic domain on APP processing.
|
Peptides
|
2007
|
0.78
|
|
14
|
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.77
|
|
15
|
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.
|
Cancer Chemother Pharmacol
|
2011
|
0.77
|
|
16
|
Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data.
|
J Breast Cancer
|
2012
|
0.76
|
|
17
|
Efficacy of exemestane in korean patients with metastatic breast cancer after failure of nonsteroidal aromatase inhibitors.
|
J Breast Cancer
|
2013
|
0.75
|
|
18
|
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2014
|
0.75
|
|
19
|
A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer.
|
Cancer Chemother Pharmacol
|
2015
|
0.75
|
|
20
|
An innate immune system-mimicking, real-time biosensing of infectious bacteria.
|
Analyst
|
2015
|
0.75
|
|
21
|
Longitudinal Association of Poor Sleep Quality With Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer.
|
Psychosom Med
|
2016
|
0.75
|
|
22
|
Apoptosis induced by ID6105, a new anthracycline (11-hydroxyaclacinomycin X, Hyrubicin), and its anti-tumor effects on experimental tumor models.
|
Cancer Chemother Pharmacol
|
2006
|
0.75
|
|
23
|
Expressive facial animation synthesis by learning speech coarticulation and expression spaces.
|
IEEE Trans Vis Comput Graph
|
2006
|
0.75
|
|
24
|
Extensive intracellular accumulation of ID-6105, a novel anthracycline, in SK-OV-3 ovarian cancer cells.
|
Arch Pharm Res
|
2008
|
0.75
|
|
25
|
Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
|
Cancer Chemother Pharmacol
|
2013
|
0.75
|
|
26
|
Diffuse large B-cell lymphoma with germinal center B-cell phenotype mimicking primary effusion lymphoma.
|
J Clin Oncol
|
2011
|
0.75
|